Delea, Thomas E <br/><br/>
Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States.  [electronic resource] 

 -  PharmacoEconomics  09 2019 
 - 1177-1193 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1179-2027 
<br/><br/><label>Standard No.: </label>10.1007/s40273-019-00812-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Bispecific--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Cost-Benefit Analysis<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Inotuzumab Ozogamicin--administration & dosage<br/>Male<br/>Middle Aged<br/>Models, Economic<br/>Precursor B-Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Quality-Adjusted Life Years<br/>Randomized Controlled Trials as Topic<br/>United States